# A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

> **NCT06772870** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Design Therapeutics, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** DT-216P2
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT06772870
- **Lead sponsor:** Design Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772870, "A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06772870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*